Core Viewpoint - The company has successfully completed the placement agreement, with all conditions met and the delivery executed on October 16, 2025 [1] Summary by Relevant Sections - The placement agent has successfully allocated a total of 24.2 million shares at a price of HKD 14.50 per share to no fewer than six subscribers [1] - This allocation represents approximately 5.94% of the company's issued share capital prior to the delivery and about 6.11% of the total issued H shares [1] - Following the delivery and issuance of the placement shares, the allocated shares will account for approximately 5.61% of the company's enlarged issued share capital and about 5.76% of the total issued H shares [1]

根据配售协议的条款及条件，配售代理已按每股配售股份14.50港元的配售价成功向不少于六名承配人 配售合共2420万股配售股份，占紧接交割前本公司已发行股本数目约5.94%及已发行H股总数约6.11%， 以及占紧随交割后经配发及发行配售股份扩大后的本公司已发行股本数目约5.61%及已发行H股总数约 5.76%。 智通财经APP讯，宜明昂科-B(01541)发布公告，配售协议所载的所有先决条件已达成且交割已根据配售 协议的条款及条件于2025年10月16日落实。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 完成根據一般授權配售新H股 獨家整體協調人、配售代理及資本市場中介人 茲提述宜明昂科生物醫藥技術（上海）股份有限公司（「本公司」）日期為2025年10 月9日的公告，內容有關根據一般授權配售新H股（「配售公告」）。除非另有界 定，否則本公告所有詞彙與配售公告所界定者具相同涵義。 本公告僅供參考之用，並不構成收購、購買或認購本公司證券的邀請或要約。 本公告及其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的任何其他司 法權區刊發或派發。 本公告並非在美國購買或認購任何證券之要約或招攬，亦不構成其一部分。本公告所述證券 並未且不會根據《1933年美國證券法》（「美國證券法」）登記，亦不會在美國提呈或出售，除非 根據美國證券法作出登記或獲豁免或為毋須根據美國證券法作出登記之交易。本公司無意根 據美國證券法登記本公告內所指之任何證券，或在美國進行證券之公開發售。 ImmuneOnco Biopharm ...

据介绍，宜明昂科开发的新一代CTLA-4抗体泰泽苏拜单抗(tazlestobart，IMM27M)通过清除肿瘤微环境 中的Treg细胞而发挥抗肿瘤疗效。目前宜明昂科正积极推进泰泽苏拜单抗的临床开发。泰泽苏拜单抗 (tazlestobart，IMM27M)是宜明昂科公司自主研发的新一代CTLA-4抗体，通过基因工程技术加强了 ADCC活性，可以全面清除肿瘤微环境中的Treg细胞。IMM27M是一种针对Treg细胞的创新药物，其主 要作用机制是通过靶向Treg细胞上的特定分子CTLA-4，调节其功能或数量，从而增强免疫反应。 消息面上，据宜明昂科-B官微消息，近日，玛丽.E.布伦科等三位科学家被授予2025年诺贝尔生理学或 医学奖，以表彰他们在外周免疫耐受机制领域的研究成果。这一创新性研究成果找到了免疫系统的抑制 开关，为全球数亿自身免疫病及癌症患者带来颠覆性疗法。调节性T细胞(Treg细胞)通过Foxp3转录因子 维持免疫耐受，其功能异常与自身免疫病、癌症等密切相关，而细胞毒性T淋巴细胞相关抗原4(CTLA- 4)是Treg细胞执行免疫抑制功能的"关键效应分子"。Treg细胞的发现及其作用机制研究，为开发新一代 ...

Core Viewpoint - The stock of Iminconco-B (01541) has risen over 5% due to increased attention on Treg cell therapy and the active clinical development of Tazlestobart monoclonal antibody [1][2] Group 1: Company Developments - Iminconco-B's stock price increased by 5.22%, reaching 11.47 HKD, with a trading volume of 40.47 million HKD [1] - The company is actively advancing the clinical development of Tazlestobart (IMM27M), a next-generation CTLA-4 antibody [2] Group 2: Scientific Recognition - Three scientists, including Mary E. Blenko, were awarded the 2025 Nobel Prize in Physiology or Medicine for their research on peripheral immune tolerance mechanisms, which has implications for autoimmune diseases and cancer therapies [1] - The discovery of regulatory T cells (Treg cells) and their mechanisms has provided a theoretical foundation for developing new immunomodulatory drugs [1] Group 3: Product Mechanism - Tazlestobart (IMM27M) is designed to eliminate Treg cells in the tumor microenvironment, enhancing anti-tumor efficacy [2] - The drug utilizes genetic engineering to enhance ADCC activity and targets specific molecules on Treg cells, particularly CTLA-4, to modulate their function or quantity [2]

Group 1 - Company Innovent Biologics (1541.HK) announced a placement of 24.2 million new H-shares, representing approximately 5.61% of the enlarged share capital, to raise HKD 351 million (USD 45 million) at a price of HKD 14.5 per share, which is a discount of about 12.97% from the previous closing price of HKD 16.66 [3] - The estimated net proceeds of approximately HKD 345 million will be used to fund the research and development of IMM2510 and IMM27M for the treatment of solid tumors, as well as for the development of IMM01 (Tislelizumab) and IMM0306, and to supplement working capital and general corporate purposes [3] - The company has submitted an application to the National Medical Products Administration for a Phase III clinical trial of IMM2510 for the treatment of immune-resistant non-small cell lung cancer (NSCLC) [3] Group 2 - The company's stock opened lower on Thursday, trading at HKD 14.46 at noon, down 13.21%. However, the stock has increased by 180% year-to-date [3]

宜明昂科-B(01541)发布公告，于2025年10月9日，公司拟配售合共2420万股新H股，占公司经配发及发 行配售股份扩大后已发行股本约5.61%。每股配售股份14.50港元的配售价，较10月8日收市价每股16.66 港元折让约12.97%。 公司自配售事项收取的所得款项总额及所得款项净额估计分别为约3.509亿港元及约3.45亿港元。公司拟 将配售事项所得款项净额应用于以下用途：(i)约40%将用于为在中国进行IMM2510及IMM27M的单一疗 法及联合疗法的研发提供资金以治疗实体瘤;(ii)约20%将用于为IMM01(替达派西普)的研发提供资金;(iii) 约10%将用于为IMM0306的研发提供资金;(iv)约30%将用于补充公司营运资金，并作一般企业用途。 ...

Core Viewpoint - The company plans to issue a total of 24.2 million new H-shares at a price of HKD 14.50 per share, representing a discount of approximately 12.97% from the closing price of HKD 16.66 on October 8, 2025 [1] Fundraising Details - The total estimated gross proceeds from the placement are approximately HKD 350.9 million, with net proceeds estimated at around HKD 345 million [1] - The net proceeds will be allocated as follows: - Approximately 40% for funding the research and development of IMM2510 and IMM27M for the treatment of solid tumors - Approximately 20% for funding the research and development of IMM01 (Tideglusib) - Approximately 10% for funding the research and development of IMM0306 - Approximately 30% for supplementing the company's working capital and general corporate purposes [1]

Core Viewpoint - The company, 宜明昂科-B (01541.HK), has announced a placement agreement with Credit Suisse to issue 24.2 million new H-shares at a price of HKD 14.50 per share, representing a discount of approximately 12.97% from the last closing price of HKD 16.66 [1] Group 1: Placement Details - The placement will involve the issuance of 24.2 million new H-shares, which accounts for about 5.94% of the company's total issued share capital and approximately 6.11% of the total issued H-shares as of the announcement date [1] - The estimated total gross proceeds from the placement are approximately HKD 350.9 million, with net proceeds expected to be around HKD 345.1 million [1] Group 2: Use of Proceeds - Approximately 40% of the net proceeds will be allocated to fund the research and development of IMM2510 and IMM27M for the treatment of solid tumors [1] - About 20% of the net proceeds will be used to fund the research and development of IMM01 (Tideglusib) [1] - Approximately 10% will be allocated for the research and development of IMM0306, while around 30% will be used to supplement the company's working capital and for general corporate purposes [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考之用，並不構成收購、購買或認購本公司證券的邀請或要約。 本公告及其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的任何其他司 法權區刊發或派發。 本公告並非在美國購買或認購任何證券之要約或招攬，亦不構成其一部分。本公告所述證券 並未且不會根據《1933年美國證券法》（「美國證券法」）登記，亦不會在美國提呈或出售，除非 根據美國證券法作出登記或獲豁免或為毋須根據美國證券法作出登記之交易。本公司無意根 據美國證券法登記本公告內所指之任何證券，或在美國進行證券之公開發售。 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 宜明昂科生物醫藥技術（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1541） 根據一般授權配售新H股 獨家整體協調人、配售代理及資本市場中介人 配售事項 董事會欣然宣佈，於2025年10月9日（ ...